Apply now to the SyDAD doctoral school — the future within Alzheimer research
The PhD programme is interdisciplinary, including an innovative research programme with cutting edge methodology, an excellent training programme, international exchanges and a translational and collaborative orientation.
”This is an opportunity of a lifetime for any PhD student within the field of neuroscience”, says Susanne Frykman, project manager and senior researcher at Karolinska Institutet´s (KI) Department of Neurobiology, Care Sciences and Society (NVS).
The doctoral students admitted to SyDAD will be educated in an environment that connects the academic world with pharmaceutical companies.
”Increased collaboration between academia, providing a huge knowledge base, and the private sector, providing understanding of the drug discovery value chain, will give a novel approach to discover new drugs and biomarkers, hopefully leading us closer to finding cures for dementia”, says Bengt Winblad, project coordinator and Professor of Geriatrics at NVS.
The European Training Network (ETN) Synaptic Dysfunction in Alzheimer Disease (SyDAD) is sponsored by Horizon 2020 Marie Sklodowska Curie Actions.
For more information about the different PhD student projects and how to apply, please see www.sydad.eu.
1. To train 15 Early Stage Researchers to a new generation of researchers with an innovative mind-set and full understanding of the requirements of academia, pharmaceutical companies, the clinics and the societal challenges.
2. To, through a collaborative research programme, elucidate how the different pathways underlying synaptic dysfunction in Alzheimer Disease relate to each other, to identify novel pharmaceutical targets and to elaborate a drug discovery platform for future implementation of the results.
Karolinska Institutet, Huddinge, Sweden (coordinator): 4 positions
University of Bordeaux, France: 3 positions
University of Milano, Italy: 3 positions
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany: 3 positions
Janssen Pharmaceuticals, Beerse, Belgium: 1 position
Axon Neuroscience, Bratislava, Slovakia: 1 position